# TORL BioTherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/torl-biotherapeutics

- Industry: Biotechnology
- Headquarters: Culver, US
- Website: www.torlbio.com/
- Total disclosed funding: $158M
- Latest round: Series B (Apr 10, 2024)
- Investors on record: 15

## About

Founded in 2018 and based in California, US, TORL BioTherapeutics, LLC is a clinical-stage biopharmaceutical firm focused on developing antibody-based therapeutics to help cancer patients. David Licata (CEO), Dennis Slamon, Mark Attanasio, and Neil O'Brien are the co-founders of the company. In October 2025, TORL BioTherapeutics, LLC raised USD 96 million in series C funding from unspecified investors.

The company provides TORL-1-23, a CLDN6-directed ADC created for patients with a variety of cancer types. An ADC and mAb targeting CLDN 18.2 are two further clinical-stage programmes offered by the business. TORL is also developing preclinical ADCs (antibody-drug conjugates) and mAbs (monoclonal antibodies) for oncologic indications.

The company will use the October 2025 funding to advance clinical trials for its Claudin 6-targeted antibody drug and support other pipeline programs.

## Funding rounds

- Series B, Apr 10, 2024 — Bristol-Myers Squibb Company, Goldman Sachs Asset Management, RA Capital Management, Perceptive Advisors, Vertex Ventures HC, Moore Strategic Ventures, Avidity Partners Management, Blue Owl, Deep Track Capital, UC Investments
- Series B, Apr 13, 2023, $158M — Healthcare Royalty Partners, Alexandria Venture Investments, Bristol-Myers Squibb Company, Goldman Sachs Asset Management, UC Ventures, Cowen Investment Management, Perceptive Advisors, Vertex Ventures HC, OCV Partners, Moore Strategic Ventures, Deep Track Capital

## Investors

- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Bristol-Myers Squibb Company — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- UC Ventures (https://capitalatlas.ai/funds/uc-ventures) — Series B
- Cowen Investment Management — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series B
- OCV Partners (https://capitalatlas.ai/funds/ocv-partners) — Series B
- Moore Strategic Ventures (https://capitalatlas.ai/funds/moore-strategic-ventures) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Avidity Partners Management — Series B
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series B
- UC Investments — Series B